Responses
Regular and young investigator award abstracts
Checkpoint blockade therapy
212 CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and synergizing with tumor-targeted antibodies
Compose a Response to This Article
Other responses
No responses have been published for this article.
